Lisa A. Raedler

797 total citations
53 papers, 649 citations indexed

About

Lisa A. Raedler is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, Lisa A. Raedler has authored 53 papers receiving a total of 649 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Hematology and 13 papers in Genetics. Recurrent topics in Lisa A. Raedler's work include Chronic Lymphocytic Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Multiple Myeloma Research and Treatments (6 papers). Lisa A. Raedler is often cited by papers focused on Chronic Lymphocytic Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Multiple Myeloma Research and Treatments (6 papers). Lisa A. Raedler collaborates with scholars based in . Lisa A. Raedler's co-authors include and has published in prestigious journals such as PubMed.

In The Last Decade

Lisa A. Raedler

50 papers receiving 637 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lisa A. Raedler	14	307	185	150	95	79	53	649
Donald R. Fleming United States	13	345 1.1×	196 1.1×	146 1.0×	71 0.7×	123 1.6×	25	740
Dalibor Valík Czechia	18	300 1.0×	474 2.6×	155 1.0×	119 1.3×	45 0.6×	73	1.1k
Yiqun Zhang United States	17	346 1.1×	288 1.6×	102 0.7×	38 0.4×	48 0.6×	36	805
Rajinder Singh India	8	199 0.6×	182 1.0×	374 2.5×	66 0.7×	48 0.6×	21	723
Ofer Margalit Israel	15	382 1.2×	330 1.8×	67 0.4×	58 0.6×	124 1.6×	52	824
Celine Pitou United States	14	289 0.9×	347 1.9×	116 0.8×	113 1.2×	82 1.0×	24	641
Laurie Gashin United States	6	209 0.7×	148 0.8×	95 0.6×	100 1.1×	121 1.5×	9	527
Gordon Moody United States	11	303 1.0×	281 1.5×	139 0.9×	90 0.9×	135 1.7×	24	836
Yoko Okitsu Japan	15	198 0.6×	320 1.7×	95 0.6×	110 1.2×	186 2.4×	49	647
Erwan Pencreach France	17	350 1.1×	323 1.7×	82 0.5×	38 0.4×	58 0.7×	35	797

Countries citing papers authored by Lisa A. Raedler

Since Specialization

Citations

This map shows the geographic impact of Lisa A. Raedler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa A. Raedler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa A. Raedler more than expected).

Fields of papers citing papers by Lisa A. Raedler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa A. Raedler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa A. Raedler. The network helps show where Lisa A. Raedler may publish in the future.

No nodes

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Raedler, Lisa A., et al.. (2018). Dupixent (Dupilumab) First Biologic Drug Approved for Patients with Moderate-to-Severe Atopic Dermatitis. 1 indexed citations

Raedler, Lisa A., et al.. (2016). Tecentriq (Atezolizumab) First PD-L1 Inhibitor Approved for Patients with Advanced or Metastatic Urothelial Carcinoma. 2 indexed citations

Raedler, Lisa A., et al.. (2016). Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma. 3 indexed citations

Raedler, Lisa A.. (2016). Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström's Macroglobulinemia.. PubMed. 9(Spec Feature). 89–92. 14 indexed citations

Raedler, Lisa A., et al.. (2016). Cabometyx (Cabozantinib) Tablets First Multikinase Inhibitor Approved for the Treatment of Patients with Advanced Renal-Cell Carcinoma. 1 indexed citations

Raedler, Lisa A.. (2016). Aripiprazole Lauroxil (Aristada): Long-Acting Atypical Antipsychotic Injection Approved for the Treatment of Patients with Schizophrenia.. PubMed. 9(Spec Feature). 40–3. 13 indexed citations

Raedler, Lisa A.. (2016). Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.. PubMed. 9(Spec Feature). 102–5. 23 indexed citations

Raedler, Lisa A.. (2016). Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma.. PubMed. 9(Spec Feature). 93–6. 7 indexed citations

Raedler, Lisa A.. (2016). Fycompa (Perampanel Hydrate) Receives Expanded Indication for Primary Generalized Tonic-Clonic Seizures.. PubMed. 9(Spec Feature). 88–88. 4 indexed citations

10.

Raedler, Lisa A.. (2016). Tresiba (Insulin Degludec Injection) and Ryzodeg 70/30 (Insulin Degludec and Insulin Aspart Injection): Two New Insulin Analogs for Glycemic Control in Diabetes Mellitus.. PubMed. 9(Spec Feature). 144–8. 8 indexed citations

11.

Raedler, Lisa A.. (2016). Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia.. PubMed. 9(Spec Feature). 123–6. 16 indexed citations

12.

Raedler, Lisa A.. (2015). Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir Tablets; Dasabuvir Tablets): All-Oral Fixed Combination Approved for Genotype 1 Chronic Hepatitis C Infection.. PubMed. 8(Spec Feature). 142–7. 39 indexed citations

13.

Raedler, Lisa A.. (2015). Soolantra (Ivermectin) 1% Cream: A Novel, Antibiotic-Free Agent Approved for the Treatment of Patients with Rosacea.. PubMed. 8(Spec Feature). 122–5. 11 indexed citations

14.

Raedler, Lisa A.. (2015). Velcade (Bortezomib) Receives 2 New FDA Indications: For Retreatment of Patients with Multiple Myeloma and for First-Line Treatment of Patients with Mantle-Cell Lymphoma.. PubMed. 8(Spec Feature). 135–40. 63 indexed citations

15.

Raedler, Lisa A.. (2015). Glyxambi (Empagliflozin/Linagliptin): A Dual-Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes.. PubMed. 8(Spec Feature). 171–5. 8 indexed citations

16.

Raedler, Lisa A.. (2015). Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting.. PubMed. 8(Spec Feature). 44–8. 5 indexed citations

17.

Raedler, Lisa A., et al.. (2015). Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma. 1 indexed citations

18.

Raedler, Lisa A., et al.. (2014). Arzerra (Ofatumumab) Receives FDA Approval for Patients with Previously Untreated Chronic Lymphocytic Leukemia for Use in Combination with Chlorambucil. 1 indexed citations

19.

Raedler, Lisa A., et al.. (2013). Gilotrif: Second-Generation Tyrosine Kinase Inhibitor Indicated for the First-Line Treatment of Patients with Non–Small-Cell Lung Cancer and EGFR Mutation. 1 indexed citations

20.

Raedler, Lisa A., et al.. (2013). Kadcyla (Ado-Trastuzumab Emtansine): First Antibody-Drug Conjugate Approved for the Treatment of HER2-Positive Metastatic Breast Cancer. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact